Wet AMD treatment expansion

Article

Oraya Therapeutics has announced that Oraya Therapy Stereotactic Radiotherapy for the treatment of wet AMD is now available at Optegra Manchester Eye Hospital.

Oraya Therapeutics has announced that Oraya Therapy Stereotactic Radiotherapy for the treatment of wet AMD is now available at Optegra Manchester Eye Hospital.

This facility is now the second in the UK to provide the therapy, which is intended as a one-time outpatient procedure. The treatment will reduce the need for routine anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

The radiotherapy involves a non-invasive, low-voltage x-ray source using advanced robotics, a laser-guided positioning system and a patented methodology for eye stabilization and tracking.

Mr Sajjad Mahmood, consultant ophthalmologist at Optegra Manchester Eye Hospital, commented, “Modern anti-VEGF injection treatments have been very successful at preventing loss of vision but patients are often anxious about having repeated eye injections. With Oraya Therapy, it is great to be able to offer patients the possibility of maintaining their vision while reducing their need for injections.”

Jim Taylor, Oraya President and Chief Executive Office, stated, “We are very encouraged by the early response and demand for Oraya Therapy since it first became available in the UK. Hundreds of patients have shown interest in the therapy and many were anxious to have a nearby treatment location in the Manchester area. There was a waiting list for Manchester already in place when the facility began treatments this month. We look to expand access and availability of this important treatment option across Europe, with several additional centers opening in the coming months.”

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.